The FDA’s 505(b)(2) pathway is an underestimated engine of value creation

News FDA Opinion: The FDA’s 505(b)(2) pathway is an underestimated engine of value creation July 21, 2026 | 6 min read | Gail McIntyre, Michelle P. Usher Twitter LinkedIn Facebook Email Print The biopharma industry would do well to re-embrace the 505(b)(2) path, which allows sponsors to draw on previous findings around an existing drug even as they propose modifications to it. In a capital environment defined by caution, skepticism and heightened demand for controlled risk, FDA’s 505(b)(2) pathway stands as one of the few remaining regulatory levers capable of accelerating innovation with some level of capital protection. Designed to enable sponsors to leverage existing efficacy and safety data for approved drugs while introducing meaningful modifications, the pathway can reduce development timelines for new therapies by several years and cut costs by tens to hundreds of millions of dollars relative to a 505(b)(1) New Drug Application.A few recent 505(b)(2) success stories illustrate how the pathway can translate into meaningful commercial outcomes when paired with clear differentiation. Pacira BioSciences’ Exparel is a long-acting liposomal formulation of the local anesthetic bupivacaine, indicated for postsurgical analgesia. By extending duration of action in a well-understood class, it enabled opioid-sparing protocols and became a cornerstone in perioperative pain management with strong hospital adoption. Xywav, by Jazz Pharmaceuticals, is a reformulated oxybate therapy for narcolepsy and idiopathic hypersomnia with approximately 92% less sodium than its predecessor; this clinically meaningful safety improvement drove rapid patient conversion and sustained franchise growth. And Axsome Therapeutics’ Auvelity combines two established agents into a novel NMDA-modulating antidepressant for major depressive disorder, delivering faster onset and differentiated efficacy compared to either drug by itself.Across these cases, success stems from the same principle: reformulating or recombining validated drugs within established classes to deliver tangible clinical or economic advantages that resonate with prescribers, patients and payers. Yet despite its track record of success and its contribution to the majority of NDAs in recent years (approximately 57% in 2024), we have observed in our consulting work at InnoDev that the 505(b)(2) pathway seems to have been re-assessed by the industry, sometimes dismissed as a shortcut at best with little upside, or other times underappreciated as an indicator that a drug is not novel.Investors have historically viewed 505(b)(2) assets with cautious optimism. On paper, the economics are striking: Published analyses suggest that repurposed medicines can reach the market with average development costs of roughly U$300 million—compared with $2–3 billion for a novel molecular entity—while also benefiting from substantially lower development risk because human safety data already exist.That relatively low risk comes with a few trade-offs. Short exclusivity windows, generic vulnerability and regulatory uncertainty stemming from the current regulatory and political environment at FDA, and from relying on public data from prior FDA reviews, which might be incomplete and mask gaps or post‑marketing safety issues that emerge during review. Because bridging needs vary widely based on how a product differs from its reference, the scope of required studies may turn out to be more significant than expected and constrain long-term upside.The investor calculus is thus nuanced: 505(b)(2)s are compelling for near-term monetization or niche markets, but are rarely the foundation for enduring franchises unless coupled with proprietary technology or platform innovation.As advisors in this space working at InnoDev Partners, we experience the same conundrum observed in the industry: should we continue to lean on the pathway as a way to bring meaningful therapies to market in areas of unmet need, or should we discourage inventors and founders from pursuing development programs aimed at the 505(b)(2) pathway in favor of drugs seen as more innovative? As laid out below, we believe that in the right circumstances, the 505(b)(2) pathway remains a useful tool to push forward innovation. A hybrid route with strategic advantages A 505(b)(2) filing occupies a unique middle ground between the “stand-alone” 505(b)(1) New Drug Application and the generic 505(j) Abbreviated NDA, leveraging prior FDA findings of safety and efficacy from a listed drug while allowing meaningful product modification. This hybrid approach makes it possible to bring improved formulations, new delivery systems or new indications to patients faster and at a fraction of the traditional cost.The regulatory advantage is significant. By referencing existing data, sponsors reduce the need for large, costly Phase 3 trials and shorten timelines, sometimes by several years. The outcome is not merely a faster path to approval but a materially lower cost of development, often reducing outlay from over a billion dollars to under $50 million. For early-stage biopharma, that delta can mean the difference between failure, and staying solvent and achieving market entry. Operational efficiency and program agility From an operational perspective, the 505(b)(2) model transforms the very architecture of drug development. Instead of building a program from the ground up, teams design efficient bridging strategies that focus on regulatory justification and data alignment. Program management becomes a discipline of integration: synchronizing chemistry, manufacturing and controls readiness, regulatory engagement and clinical pharmacology to ensure that every reference to existing data is scientifically defensible.This streamlined model encourages faster decision-making and tighter cross-functional coordination. Compared with the long, risk-laden timelines of a new chemical entity, 505(b)(2) development can move with startup-like agility while still meeting FDA rigor. Commercial promise—and its caveats Commercially, 505(b)(2) programs offer a rare alignment of regulatory speed, clinical logic and economic efficiency. For investors, they represent tangible, near-term value inflection points: earlier proof of concept, faster time to revenue and often lower biological risk. Indeed, when executed correctly—with strong differentiation and clear payer logic—the pathway can yield some of the most capital-efficient successes in biopharma.Yet the same factors that make the model appealing also invite scrutiny. Market exclusivity, typically three to five years after approval of a 505(b)(2) application, is limited compared to the 12-year protection of drugs approved under standalone NDAs. Relying on known active ingredients weakens the intellectual-property moat, making differentiation essential. Products that fail to deliver meaningful clinical or economic advantages risk being seen as incremental and priced accordingly. In saturated markets, even a modestly improved therapy can be commercially overlooked if the value story is not compellingly built for prescribers, payers and patients. When to choose the 505(b)(2) route The 505(b)(2) framework is not a regulatory loophole, but an instrument of purposeful innovation. When used well—to advance patient access, reduce costs of care or modernize delivery—it embodies the very spirit of pragmatic innovation the healthcare system needs. But sponsors must resist the temptation to treat it as a shortcut to market. The FDA has grown more demanding, requiring robust bridging data and meaningful differentiation. The sponsor of a 505(b)(2) application needs to carefully consider the strategy, and factors such as: what data are available, and are those data sufficient for the regulatory agency to bridge to the new application? Is the return on investment sufficient for the estimated time and costs of development?Those who invest early in clinical, regulatory and market access clarity will find the pathway not just viable, but transformative. As the biopharma ecosystem faces escalating capital scarcity and payer pressure, the industry would do well to re-embrace the 505(b)(2) path, not as a second-tier route, but as a strategy to deliver smarter innovation faster. For founders, investors and regulators alike, that shift in mindset could redefine how value, risk and speed are balanced in the next wave of therapeutic advancement. Twitter LinkedIn Facebook Email Print Opinion Drug discovery FDA Regulatory Gail McIntyre Gail McIntyre, Ph.D., is a partner at InnoDev Partners LLC. Michelle P. Usher Michelle Usher is a partner at InnoDev Partners LLC.